{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T07:15:53Z","timestamp":1756192553882,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1245\/s10434-020-09202-1","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T18:09:22Z","timestamp":1602785362000},"page":"1740-1748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Significance of Malignant Peritoneal Cytology on Survival of Women with Uterine Sarcoma"],"prefix":"10.1245","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-8701","authenticated-orcid":false,"given":"Koji","family":"Matsuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Nusbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohee","family":"Ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica J.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Klar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda D.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"9202_CR1","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/JCO.2017.75.9845","volume":"36","author":"S George","year":"2018","unstructured":"George S, Serrano C, Hensley ML, Ray-Coquard I. Soft tissue and uterine leiomyosarcoma. J Clin Oncol. 2018;36:144\u201350.","journal-title":"J Clin Oncol."},{"key":"9202_CR2","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ygyno.2018.09.010","volume":"151","author":"ME Roberts","year":"2018","unstructured":"Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: A review of the literature and update on management options. Gynecol Oncol. 2018;151:562\u201372.","journal-title":"Gynecol Oncol."},{"key":"9202_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.currproblcancer.2019.06.001","volume":"43","author":"KN Ganjoo","year":"2019","unstructured":"Ganjoo KN. Uterine sarcomas. Curr Probl Cancer. 2019;43:283\u20138.","journal-title":"Curr Probl Cancer."},{"key":"9202_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ygyno.2017.02.019","volume":"145","author":"S Ricci","year":"2017","unstructured":"Ricci S, Stone RL, Fader AN. Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation. Gynecol Oncol. 2017;145:208\u201316.","journal-title":"Gynecol Oncol."},{"key":"9202_CR5","unstructured":"National Cancer Institute\u2019s The Surveillance, Epidemiology, and End Results (SEER) Program. Available at: http:\/\/seer.cancer.gov\/. Accessed 14 Apr 2020."},{"key":"9202_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijgo.2008.12.009","volume":"104","author":"FIGO staging for uterine sarcomas","year":"2009","unstructured":"FIGO staging for uterine sarcomas. Int J Gynecol Obstet. 2009;104:179.","journal-title":"Int J Gynecol Obstet."},{"key":"9202_CR7","doi-asserted-by":"crossref","unstructured":"Corrigendum to \u201cFIGO staging for uterine sarcomas\u201d [International Journal of Gynecology and Obstetrics (2009) 104:179]. Int J Gynecol Obstet. 2009;106:277.","DOI":"10.1016\/j.ijgo.2009.04.002"},{"key":"9202_CR8","unstructured":"Uterine sarcoma stages. Available at: https:\/\/www.cancer.org\/cancer\/uterine-sarcoma\/detection-diagnosis-staging\/staging.html. Accessed 14 Apr 2020."},{"key":"9202_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ygyno.2012.09.026","volume":"128","author":"G Garg","year":"2013","unstructured":"Garg G, Gao F, Wright JD, Hagemann AR, Mutch DG, Powell MA. Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. Gynecol Oncol. 2013;128:77\u201382.","journal-title":"Gynecol Oncol."},{"key":"9202_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ygyno.2018.02.012","volume":"149","author":"K Matsuo","year":"2018","unstructured":"Matsuo K, Yabuno A, Hom MS, Shida M, Kakuda M, Adachi S, et al. Significance of abnormal peritoneal cytology on survival of women with stage I\u2013II endometrioid endometrial cancer. Gynecol Oncol. 2018;149:301\u20139.","journal-title":"Gynecol Oncol."},{"key":"9202_CR11","doi-asserted-by":"crossref","unstructured":"Prat J, Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1\u20135.","DOI":"10.1016\/j.ijgo.2013.10.001"},{"key":"9202_CR12","doi-asserted-by":"crossref","unstructured":"Matsuo K, Shimada M, Matsuzaki S, Machida H, Nagase Y, Saito T, et al. Significance of malignant peritoneal cytology on the survival of women with early-stage cervical cancer: a Japanese Gynecologic Oncology Group Study. J Clin Med. 2019;8.","DOI":"10.3390\/jcm8111822"},{"key":"9202_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejca.2020.03.031","volume":"133","author":"K Matsuo","year":"2020","unstructured":"Matsuo K, Matsuzaki S, Nusbaum DJ, Machida H, Nagase Y, Grubbs BH, et al. Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. Eur J Cancer. 2020;133:33\u201346.","journal-title":"Eur J Cancer."},{"key":"9202_CR14","doi-asserted-by":"crossref","unstructured":"Matsuo K, Nusbaum DJ, Matsuzaki S, Chang EJ, Roman LD, Wright JD, et al. Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer. Gynecol Oncol. 2020 (in press).","DOI":"10.1016\/j.ygyno.2020.07.010"},{"key":"9202_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/00000421-200206000-00010","volume":"25","author":"G El Husseiny","year":"2002","unstructured":"El Husseiny G, Al Bareedy N, Mourad WA, Mohamed G, Shoukri M, Subhi J, et al. Prognostic factors and treatment modalities in uterine sarcoma. Am J Clin Oncol. 2002;25:256\u201360.","journal-title":"Am J Clin Oncol."},{"key":"9202_CR16","first-page":"750","volume":"36","author":"J Visnovsky","year":"2015","unstructured":"Visnovsky J, Kudela E, Slavik P, Krkoska M, Buocik P, Szepe P, et al. Survival and risk factors associated with uterine sarcomas and carcinosarcomas in stage I and II. Neuro Endocrinol Lett. 2015;36:750\u20137.","journal-title":"Neuro Endocrinol Lett."},{"key":"9202_CR17","first-page":"46","volume":"29","author":"D Yalman","year":"2008","unstructured":"Yalman D, Ozsaran Z, Baltalarli B, Demir O, Ozdemir N, Aras A. Results of postoperative radiotherapy in the treatment of uterine sarcomas: a retrospective analysis of 46 patients. Eur J Gynaecol Oncol. 2008;29:46\u201351.","journal-title":"Eur J Gynaecol Oncol."},{"key":"9202_CR18","unstructured":"National Cancer Registrars Association. Available at: http:\/\/www.ncra-usa.org\/i4a\/pages\/index.cfm?pageid=1%3e. Accessed 14 Apr 2020."},{"issue":"Suppl 23","key":"9202_CR19","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1002\/cncr.29054","volume":"120","author":"PM Jamison","year":"2014","unstructured":"Jamison PM, Altekruse SF, Chang JT, Zahn J, Lee R, Noone AM, et al. Site-specific factors for cancer of the corpus uteri from SEER registries: collaborative stage data collection system, version 1 and version 2. Cancer. 2014;120 Suppl 23:3836\u201345.","journal-title":"Cancer."},{"key":"9202_CR20","unstructured":"Corpus sarcoma. Collaborative Stage Data Set. Available at: http:\/\/web2.facs.org\/cstage0205\/corpussarcoma\/CorpusSarcomaschema.html. Accessed 14 Apr 2020."},{"key":"9202_CR21","unstructured":"American Joint Committee on Cancer. https:\/\/cancerstaging.org\/Pages\/default.aspx. Accessed 14 Apr 2020."},{"key":"9202_CR22","unstructured":"International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3). World Health Organization. https:\/\/www.who.int\/classifications\/icd\/adaptations\/oncology\/en\/. Accessed 14 April 2020."},{"key":"9202_CR23","unstructured":"National Death Index. Available at: https:\/\/www.cdc.gov\/nchs\/ndi\/. Accessed 14 Apr 2019."},{"key":"9202_CR24","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/(SICI)1097-0258(19970515)16:9<965::AID-SIM509>3.0.CO;2-O","volume":"16","author":"DW Hosmer","year":"1997","unstructured":"Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med. 1997;16:965\u201380.","journal-title":"Stat Med."},{"key":"9202_CR25","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","volume":"37","author":"L Gaspar","year":"1997","unstructured":"Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745\u201351.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"9202_CR26","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Statist Med. 2015;34:3661\u201379.","journal-title":"Statist Med."},{"key":"9202_CR27","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1200\/JCO.2012.41.6701","volume":"30","author":"DL Hershman","year":"2012","unstructured":"Hershman DL, Wright JD. Comparative effectiveness research in oncology methodology: observational data. J Clin Oncol. 2012;30:4215\u201322.","journal-title":"J Clin Oncol."},{"key":"9202_CR28","doi-asserted-by":"publisher","first-page":"103.e1","DOI":"10.1016\/j.ajog.2019.12.273","volume":"223","author":"RS Mandelbaum","year":"2020","unstructured":"Mandelbaum RS, Ciccone MA, Nusbaum DJ, Khoshchehreh M, Purswani H, Morocco EB, et al. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy. Am J Obstet Gynecol. 2020;223:103.e1\u2013103.e13.","journal-title":"Am J Obstet Gynecol."},{"key":"9202_CR29","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Hillsdale, NJ: Erlbaum; 1988.","edition":"2"},{"key":"9202_CR30","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1002\/sim.3854","volume":"29","author":"PC Austin","year":"2010","unstructured":"Austin PC. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Stat Med. 2010;29:2137\u201348.","journal-title":"Stat Med."},{"key":"9202_CR31","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ (Clinical Research ed). 2007;335:806\u20138.","journal-title":"BMJ (Clinical Research ed)."},{"key":"9202_CR32","first-page":"173","volume-title":"Clinical gynecologic oncology","author":"Sarcoma of the uterus","year":"2002","unstructured":"Sarcoma of the uterus. In: DiSaia PJ, Creasman WT (eds) Clinical gynecologic oncology, 6th edn. St. Louis: Mosby; 2002, pp 173\u201385.","edition":"6"},{"key":"9202_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00004347-199204000-00001","volume":"11","author":"T Kaku","year":"1992","unstructured":"Kaku T, Silverberg SG, Major FJ, Miller A, Fetter B, Brady MF. Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases. Int J Gynecol Pathol. 1992;11:75\u201388.","journal-title":"Int J Gynecol Pathol."},{"key":"9202_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaoncol.2014.206","volume":"1","author":"JD Wright","year":"2015","unstructured":"Wright JD, Tergas AI, Cui R, Burke WM, Hou JY, Ananth CV, et al. Use of electric power morcellation and prevalence of underlying cancer in women who undergo myomectomy. JAMA Oncol. 2015;1:69\u201377.","journal-title":"JAMA Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09202-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T03:28:40Z","timestamp":1634268520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09202-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["9202"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09202-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"14 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ensign Endowment for Gynecologic Cancer Research (K.M.).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding support"}},{"value":"The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the Funding Source"}},{"value":"The manuscript\u2019s corresponding author (K.M.) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. Surveillance, Epidemiology, and End Results Program is managed by the National Cancer Institute in the United States, and the program is the source of the deidentified data used. The program has not verified and is not responsible for the statistical validity of the data analysis or the conclusions derived by the study team.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency"}}]}}